Reishi D. International, Inc.

CLOSEOUT LETTER Reishi D. International, Inc. MARCS-CMS 537352 — November 27, 2018 More Warning Letters Warning Letters About Warning and Close-Out Letters Product: Dietary Supplements Recipient: Recipient Name Zheng Xiong Li Recipient Title CEO Reishi D. International, Inc. 451 Victory Ave Suite 3 South San Francisco , CA 94080 United States Issuing Office: Office Human and Animal Foods Division West 5 1431 Harbor Bay Parkway Alameda , CA 94502-7070 United States Dear Mr. Zheng Xiong Li: The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter (CMS # 537352), dated February 06, 2018. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ Robert B. Mcnab for/ Sergio Chavez, Director of Compliance Office Human and Animal Foods Division West 5 Content current as of: 10/08/2019 Regulated Product(s) Dietary Supplements